<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681432</url>
  </required_header>
  <id_info>
    <org_study_id>HGCRCIRU001</org_study_id>
    <nct_id>NCT02681432</nct_id>
  </id_info>
  <brief_title>Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer</brief_title>
  <acronym>hipecova</acronym>
  <official_title>Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel for the Treatment of Patients With Recurrent or Primary Advanced Ovarian Cancer : A Randomised Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PEDRO VILLAREJO CAMPOS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital General de Ciudad Real</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Castilla-La Mancha</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General de Ciudad Real</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized clinical trial to asses the efficacy of closed abdomen hyperthermia
      intraperitoneal chemotherapy with paclitaxel in ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized clinical trial performed in woman with epithelial primary ovarian cancer (stage
      FIGO II, III and IV) or tumor recurrence. A cytoreductive surgery will be perform in all of
      the patients include in the trial, and it will be assign at randomization:

        -  HIPEC-arm: cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with
           paclitaxel (175 mg / m2) for 60 minutes at a temperature of 42-43º degrees; followed by
           postoperative systemic IV chemotherapy with carboplatin (AUC=6) and paclitaxel (175
           mg/m2) for 6 cycles.

        -  No HIPEC-arm: Cytoreductive surgery followed by postoperative systemic IV chemotherapy
           with carboplatin (AUC=6) and paclitaxel (175 mg/m2) for 6 cycles.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 6 months till 36 months</time_frame>
    <description>From the date of surgery to the date of death or to the end of study (follow up every 6 months till 3 years)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>follow up every 6 months till 18 months</time_frame>
    <description>From the date of surgery to the date of recurrence or to the end of study (follow up every 6 months till 18 months)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Post-operative complications</measure>
    <time_frame>adverse events within 30 days postoperatively (according to NCI criteria, Common Terminology Criteria for AE (CTCAE))</time_frame>
    <description>Compare adverse events between study arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primary ovarian cancer FIGO stage II, III or IV or recurrent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No HIPEC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primary ovarian cancer FIGO stage II, III or IV or recurrent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIPEC</intervention_name>
    <description>Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.</description>
    <arm_group_label>HIPEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No HIPEC</intervention_name>
    <description>Cytoreductive surgery without HIPEC</description>
    <arm_group_label>No HIPEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with histologically confirmed epithelial ovarian cancer (stage II / III / IV
             disease of FIGO) or tumor recurrences (the women of childbearing age need to have a
             negative pregnancy test)

          -  Complete cytoreduction: Index CC0/CC1 cytoreduction (residual tumor size after
             surgery, no visible (CC0) or less than 0.25 cm (CC1))

          -  No extra-abdominal tumor disease

          -  Absence of heart failure. Adequate renal and hepatic functions

          -  Eastern Cooperative Oncology Group performance status 0-2 or Karnofsky performance
             status ≥ 70%

        Exclusion Criteria:

          -  Patients with unresectable tumor or incomplete cytoreduction.

          -  Contraindications for treatment with paclitaxel: patients with severe hypersensitivity
             to paclitaxel or any of the excipients,pregnancy or lactation and patients with
             baseline neutrophil count &lt;1.500/mm3 (&lt;1.000/mm3 for patients with Kaposi sarcoma).
             Paclitaxel is also contraindicated in patients who have concurrent and severe
             infections.

          -  Extra-abdominal metastases or unresectable liver metastases

          -  Presence of other malignant tumor disease.

          -  Multisegmental complete bowel obstruction.

          -  Patients with severe medical problems that will preclude compliance with the study or
             with an unacceptable risk

          -  Patients who refuse treatment or consent to participate in study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Villarejo Campos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SESCAM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Villarejo Campos, MD,PhD</last_name>
    <phone>926278000</phone>
    <phone_ext>79784</phone_ext>
    <email>villarejocampos@yahoo.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital General Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Redondo-Calvo, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Pedro Villarejo Campos, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Redondo Calvo, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Muñoz-Casares FC, Rufián S, Rubio MJ, Díaz CJ, Díaz R, Casado A, Arjona A, Muñoz-Villanueva MC, Muntané J. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol. 2009 Nov;11(11):753-9.</citation>
    <PMID>19917539</PMID>
  </reference>
  <reference>
    <citation>Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016 Jan 12;(1):CD005340. doi: 10.1002/14651858.CD005340.pub4. Review.</citation>
    <PMID>26755441</PMID>
  </reference>
  <reference>
    <citation>Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43.</citation>
    <PMID>16394300</PMID>
  </reference>
  <reference>
    <citation>Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009 Dec;135(12):1637-45. doi: 10.1007/s00432-009-0667-4. Epub 2009 Aug 23. Review.</citation>
    <PMID>19701772</PMID>
  </reference>
  <reference>
    <citation>Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol. 2007 Dec;18(12):1943-50. Epub 2007 May 11.</citation>
    <PMID>17496308</PMID>
  </reference>
  <reference>
    <citation>Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Lee KH, Lee SH, Kim SJ. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol. 2010 Feb 1;101(2):149-55. doi: 10.1002/jso.21448.</citation>
    <PMID>20035540</PMID>
  </reference>
  <reference>
    <citation>Benedetti Panici P, Palaia I, Graziano M, Bellati F, Manci N, Angioli R. Intraperitoneal paclitaxel as consolidation treatment in ovarian cancer patients: a case control study. Oncology. 2010;78(1):20-5. doi: 10.1159/000287968. Epub 2010 Feb 24.</citation>
    <PMID>20185937</PMID>
  </reference>
  <reference>
    <citation>de Bree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, Daskalakis M, Pilatou M, Sanidas E, Taflampas P, Kalbakis K, Beijnen JH, Tsiftsis DD. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol. 2008 Apr;15(4):1183-92. doi: 10.1245/s10434-007-9792-y. Epub 2008 Feb 1.</citation>
    <PMID>18239973</PMID>
  </reference>
  <reference>
    <citation>Seretis C, Youssef H. Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review. Eur J Surg Oncol. 2014 Dec;40(12):1605-13. doi: 10.1016/j.ejso.2014.08.477. Epub 2014 Sep 6. Review.</citation>
    <PMID>25242382</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2016</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Ciudad Real</investigator_affiliation>
    <investigator_full_name>PEDRO VILLAREJO CAMPOS</investigator_full_name>
    <investigator_title>MD, PhD.Associate Professor of Surgery. University of Castilla-La Mancha</investigator_title>
  </responsible_party>
  <keyword>HIPEC</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>peritoneal carcinomatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

